Resources Repository
-
OrganizationWeb Portal 2024One Health Trust
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded …
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded with the objective of using research to support better decision-making in health policy. One Health Trust researchers employ a range of expertise—including economics, epidemiology, disease modeling, risk analysis, and statistics—to conduct actionable, policy-oriented research on malaria, antibiotic resistance, disease control priorities, environmental health, alcohol and tobacco, and other global health priorities. One Health Trust projects are global in scope, spanning…
Cost-Effectiveness Analysis | Health Outcomes | Costing Methods | Mathematical Models | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Social Determinants | Environmental Health | Policy/Regulation | Climate/Environment | Economics/Finance | Health/Medicine | Global | Sub-Saharan Africa | Asia & Pacific -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Cost-Effectiveness Analysis | Health Outcomes | Costing Methods | Test Performance | Decision Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America -
OrganizationWeb Portal 2024Center for the Evaluation of Value and Risk in Health (CEVR)
CEVR, the Center for the Evaluation of Value and Risk in Health, at Tufts Medical …
CEVR, the Center for the Evaluation of Value and Risk in Health, at Tufts Medical Center was established in 2005 and analyzes the benefits, risks and costs of strategies to improve health and health care. CEVR undertakes projects to determine the cost-effectiveness of health care interventions, including customized analyses for government agencies, private foundations and industry groups. CEVR has developed and maintains two internationally-known databases for health care stakeholders: the Cost-Effectiveness Analysis Registry and the National Coverage Determinations…
Cost-Effectiveness Analysis | Health Outcomes | Technology Assessment | Health Systems | Health/Medicine | North America -
OrganizationWeb Portal 2024ISOQOL
The International Society for Quality of Life Research (ISOQOL), established in 1993, is a non-profit …
The International Society for Quality of Life Research (ISOQOL), established in 1993, is a non-profit society to advance the scientific study of health-related quality of life and other patient-centered outcomes to identify effective interventions, enhance the quality of health care and promote the health of populations. ISOQOL provides a networking opportunity for those in the quality of life research field. ISOQOL fosters exchange of information through: scientific publications, international conferences, educational short-courses and online webinars, and collaborative…
Preferences/Values | Health Outcomes | Health/Medicine | Global -
ReviewPublication 2016Cost-Effectiveness Studies Reporting Cost-per-DALY Averted
This is a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015 …
This is a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015 conducted using the Global Health Cost-Effectiveness Analysis (GHCEA) Registry. Authors summarized descriptive characteristics on study methodology. They analyzed a) the types of costs included, b) study quality and c) the correlation between diseases researched and the burden of disease in different world regions. 479 cost-per-DALY averted studies were published from 2000 through 2015, with studies from Sub-Saharan Africa representing the largest portion…
Cost-Effectiveness Analysis | Health Outcomes | Health Systems | Health/Medicine | Global -
ReviewWeb Portal 2016Use of Economics in Informing U.S. Public Health Policy
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics …
The goal of this American Journal of Preventive Medicine supplement on “The Use of Economics in Informing U.S. Public Health Policy” is to influence policy researchers to identify and undertake economic research that generates the key evidence needed to inform policy. In public health, economic evaluation, primarily cost and cost-effectiveness analysis, has been widely used to demonstrate the economic burden of health-related conditions and the value of proposed programs and policies. However, despite the wealth…
Cost-Effectiveness Analysis | Health Outcomes | Priority Setting/Ethics | Costing Methods | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | North America -
ReviewPublication 2016Strengthening Cost-Effectiveness Analysis for Public Health Policy
Many important opportunities to improve health lie outside the health sector and involve improving the …
Many important opportunities to improve health lie outside the health sector and involve improving the conditions in which we live and work: safe design and maintenance of roads, bridges, train tracks, and airports; control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food supply; safe manufacture of consumer products; a healthy social environment; and others. Faced with the overwhelming array of possibilities, U.S. decision makers need help identifying those that can contribute the…
Preferences/Values | Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Social Determinants | Environmental Health | Health Systems | Policy/Regulation | Climate/Environment | Economics/Finance | Food/Agriculture | Health/Medicine | North America -
ReviewPublication 2006Ethical Issues in Resource Allocation, Research, and New Product Development
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care …
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care are most acute when needs are great and resources few. This chapter from the Disease Control Priorities in Developing Countries 2nd edition addresses some of these concerns, identifying some of the principal ethical issues that arise in the development and allocation of effective interventions for developing countries and discussing some alternative resolutions. Resource allocation in health and elsewhere should satisfy two main…
Preferences/Values | Cost-Effectiveness Analysis | Priority Setting/Ethics | Culture/Society | Government/Law | Health/Medicine | Science/Technology -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America